📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Allakos

1.1 - Company Overview

Allakos Logo

Allakos

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of therapeutic antibodies for allergy, inflammatory and proliferative diseases, including AK006, a humanized IgG1 monoclonal antibody targeting Siglec-6 to inhibit mast cell activation and reduce mast cell numbers via antibody-dependent cellular phagocytosis, and AK007, a humanized Siglec-10 antagonist that blocks ligand interaction to restore macrophage and dendritic cell anti-tumor activity and promote anti-tumor immunity.

Products and services

  • Therapeutic Antibody Development: target-specific program develops therapeutic antibodies for allergy, inflammatory, and proliferative diseases, including Siglec-6 and Siglec-10 targets
  • AK007: humanized antagonist antibody against Siglec-10 that blocks ligand interactions to restore macrophage and dendritic cell anti-tumor activity and promote anti-tumor immunity
  • AK006: humanized IgG1 monoclonal antibody targeting Siglec-6, engineered to inhibit mast cell activation and reduce mast cell numbers via antibody-dependent cellular phagocytosis

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Allakos

Telavant Logo

Telavant

HQ: United States Website
  • Description: Provider of novel medicines in development to assist patients suffering from inflammatory and fibrotic disorders.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Telavant company profile →
Sucampo Pharmaceuticals Logo

Sucampo Pharmaceuticals

HQ: United States Website
  • Description: Provider of specialized biopharmaceuticals addressing unmet medical needs, with marketed products AMITIZA for chronic constipation and IBS-C in adults and RESCULA in Japan for lowering intraocular pressure in glaucoma or ocular hypertension, and a late-stage pipeline including VTS-270 for Niemann-Pick Disease Type C and CPP-1X/sulindac for Familial Adenomatous Polyposis.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Sucampo Pharmaceuticals company profile →
Gossamer Bio Logo

Gossamer Bio

HQ: United States Website
  • Description: Provider of biopharmaceutical discovery and development of novel and differentiated therapeutic products, including seralutinib for pulmonary arterial hypertension in Phase 3 clinical trials, and offering clinical trials and an expanded access program for investigational medicines.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Gossamer Bio company profile →
Moderna Logo

Moderna

HQ: United States Website
  • Description: Provider of mRNA-based vaccines and therapeutics, including SPIKEVAX (FDA-approved COVID-19 vaccine), mRESVIA (RSV vaccine for older adults), and pipeline candidates mRNA-1283 (next-gen COVID, Phase 3), mRNA-1010 (flu, Phase 3), mRNA-1647 (CMV, Phase 3), and mRNA-4157 (individualized neoantigen cancer therapy, in collaboration with Merck).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Moderna company profile →
ADMA Biologics Logo

ADMA Biologics

HQ: United States Website
  • Description: Provider of plasma-based biologics, including ASCENIV IVIG for primary immunodeficiency disease (PIDD) and other immune-compromised conditions; BIVIGAM IVIG for primary humoral immunodeficiency (PI); Nabi-HB hyperimmune globulin to prevent hepatitis B infection following exposure; and ADMA BioCenters, a network of plasma collection centers supplying high-quality plasma for immunoglobulin manufacturing.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ADMA Biologics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Allakos

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Allakos

2.2 - Growth funds investing in similar companies to Allakos

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Allakos

4.2 - Public trading comparable groups for Allakos

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Allakos

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Allakos

What does Allakos do?

Allakos is a provider of therapeutic antibodies for allergy, inflammatory and proliferative diseases, including AK006, a humanized IgG1 monoclonal antibody targeting Siglec-6 to inhibit mast cell activation and reduce mast cell numbers via antibody-dependent cellular phagocytosis, and AK007, a humanized Siglec-10 antagonist that blocks ligand interaction to restore macrophage and dendritic cell anti-tumor activity and promote anti-tumor immunity.

Who are Allakos's competitors?

Allakos's competitors and similar companies include Telavant, Sucampo Pharmaceuticals, Gossamer Bio, Moderna, and ADMA Biologics.

Where is Allakos headquartered?

Allakos is headquartered in United States.

How many employees does Allakos have?

Allakos has 1,000 employees 🔒.

When was Allakos founded?

Allakos was founded in 2010 🔒.

What sector and industry vertical is Allakos in?

Allakos is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Allakos

Who are the top strategic acquirers in Allakos's sector and industry

Top strategic M&A buyers and acquirers in Allakos's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Allakos?

Top strategic M&A buyers groups and sectors for Allakos include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Allakos's sector and industry vertical

Which are the top PE firms investing in Allakos's sector and industry vertical?

Top PE firms investing in Allakos's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Allakos's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Allakos's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Allakos's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Allakos include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Allakos's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Allakos?

The key public trading comparables and valuation benchmarks for Allakos include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Allakos for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Allakos with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Allakos's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Allakos with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Allakos's' sector and industry vertical?

Access recent funding rounds and capital raises in Allakos's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Allakos

Launch login modal Launch register modal